Zoetis (ZTS) Stock Climbing Before Tomorrow’s Earnings Release

NEW YORK (TheStreet) -- Shares of Zoetis Inc. (ZTS) are higher by 1.82% to $45.42 in late afternoon trading on Monday, one day before the veterinary drug maker releases its 2015 first quarter earnings results. Zoetis will issue its financial report before the market open on Tuesday morning.

Analysts are expecting that the company will post a slight decline in its earnings per share data and revenue that is in-line with its year-ago first quarter results.

The company has been forecast to report earnings of 37 cents per share on revenue of $1.11 billion for the quarter ended March 2015.

Last year Zoetis said its adjusted earnings were 38 cents per share on revenue of $1.1 billion for the 2014 first quarter. The company's year ago earnings results improved from the 2013 first quarter by 6% and 1% respectively.

Based in Florham Park, NJ, Zoetis discovers, develops, manufacturers, and commercializes medicines and vaccines for animal health. The company focuses on both livestock and companion animals.

Separately, TheStreet Ratings team rates ZOETIS INC as a Buy with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:

"We rate ZOETIS INC (ZTS) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."

If you liked this article you might like

These Stocks Have Changed Direction

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Zoetis: Cramer's Top Takeaways